Cerebral's workforce strategy from 2020 to 2026, based strictly on available data, reveals a distinct period of significant contraction and operational restructuring commencing in mid-2022. The company initiated substantial layoffs in July 2022, explicitly tied to an operational restructure amid a federal investigation, marking a clear pivot towards consolidation. This trend of workforce reduction accelerated, with an additional 20% staff cut implemented by October 2022. The strategic realignment persisted into early 2023, culminating in the closure of its Medication-Assisted Treatment Program and a further 15% staff reduction by February 2023. These successive actions collectively underscore a reactive posture to both external regulatory scrutiny and internal programmatic adjustments, prioritizing a leaner operational footprint. The provided data exclusively details these periods of reduction and restructuring, offering no indication of prior expansion phases, subsequent workforce growth, or stabilization through 2026. Furthermore, the stated justifications for these reductions are limited to operational restructuring and program closure, without explicit mention of broader efficiency drives or a strategic refocus on artificial intelligence. The observed trajectory is one of sustained workforce scaling back in direct response to specific programmatic and investigatory challenges.